10. Mycophenolate mofetil (Myora®) - Teratogenicity - Educational materials - spontaneous abortions for HCPs & patients. - congenital malformations following exposure during pregnancy. 11. Mycophenolic acid (Myfortic®) - Teratogenicity - Educational materials - spontaneous abortions for HCPs & patients. - congenital malformations following exposure during pregnancy. 12. Mycophenolate mofetil - Teratogenicity - Educational materials - spontaneous abortions (Mofetab®) for HCPs & patients. - congenital malformations following exposure during pregnancy. 13. Infliximab (Remicade®) - - Risk of infection Infusion card, - Risk of Cancer - HCP safety sheet 14. Infliximab (Remsima®) - Risk of infection - Infusion card, - Risk of Cancer - HCP safety 15. Rituximab (Mabthera®) - - Infections (including serious infections) Patient alert card(for Progressive Multifocal leukoencephalopathy RA and GPA/MPA indications only). - Educational Material for healthcare professional and patients(for RA & GPA/MPA indications only). 16. Rituximab (Mabthera® S.C) - - Off-lable use of the Subcutaneous Formulation indication: Educational Material (subcutaneous formulation NHL/CLLonly) for Healthcare – - administration route error indication (subcutaneous Professionals) formulation NHL/CLLonly) –
10. Mycophenolate mofetil (Myora®) - Teratogenicity - spontaneous abortions - congenital malformations following exposure during pregnancy. - Educational materials for HCPs & patients. 11. Mycophenolic acid (Myfortic®) - Teratogenicity - spontaneous abortions - congenital malformations following exposure during pregnancy. - Educational materials for HCPs & patients. 12. Mycophenolate mofetil (Mofetab®) - Teratogenicity - spontaneous abortions - congenital malformations following exposure during pregnancy. - Educational materials for HCPs & patients. 13. Infliximab (Remicade®) - Risk of infection - Risk of Cancer - Infusion card, - HCP safety sheet 14. Infliximab (Remsima®) - Risk of infection - Risk of Cancer - Infusion card, - HCP safety 15. Rituximab (Mabthera®) - Infections (including serious infections) Progressive Multifocal leukoencephalopathy - Patient alert card(for RA and GPA/MPA indications only). - Educational Material for healthcare professional and patients(for RA & GPA/MPA indications only). 16. Rituximab (Mabthera® S.C) - Off-lable use of the Subcutaneous Formulation indication: (subcutaneous formulation – NHL/CLLonly) - administration route error indication (subcutaneous formulation – NHL/CLLonly) - Educational Material for Healthcare Professionals)
Risk%20minimization%20activity.docx